Ensysce Biosciences (ENSC) Competitors $2.13 -0.03 (-1.39%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$2.12 -0.01 (-0.47%) As of 07/18/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ENSC vs. RLMD, RVPH, FNCH, VYNE, CING, BLRX, MEIP, AYTU, HOTH, and CARMShould you be buying Ensysce Biosciences stock or one of its competitors? The main competitors of Ensysce Biosciences include Relmada Therapeutics (RLMD), Reviva Pharmaceuticals (RVPH), Finch Therapeutics Group (FNCH), VYNE Therapeutics (VYNE), Cingulate (CING), BioLineRx (BLRX), MEI Pharma (MEIP), Aytu BioPharma (AYTU), Hoth Therapeutics (HOTH), and Carisma Therapeutics (CARM). These companies are all part of the "pharmaceutical products" industry. Ensysce Biosciences vs. Its Competitors Relmada Therapeutics Reviva Pharmaceuticals Finch Therapeutics Group VYNE Therapeutics Cingulate BioLineRx MEI Pharma Aytu BioPharma Hoth Therapeutics Carisma Therapeutics Ensysce Biosciences (NASDAQ:ENSC) and Relmada Therapeutics (NASDAQ:RLMD) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, profitability, dividends, analyst recommendations, risk, media sentiment and institutional ownership. Is ENSC or RLMD more profitable? Relmada Therapeutics has a net margin of 0.00% compared to Ensysce Biosciences' net margin of -109.49%. Relmada Therapeutics' return on equity of -181.26% beat Ensysce Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Ensysce Biosciences-109.49% -192.54% -121.77% Relmada Therapeutics N/A -181.26%-151.23% Do insiders & institutionals have more ownership in ENSC or RLMD? 5.6% of Ensysce Biosciences shares are owned by institutional investors. Comparatively, 45.2% of Relmada Therapeutics shares are owned by institutional investors. 7.9% of Ensysce Biosciences shares are owned by company insiders. Comparatively, 20.7% of Relmada Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Does the media refer more to ENSC or RLMD? In the previous week, Ensysce Biosciences and Ensysce Biosciences both had 2 articles in the media. Relmada Therapeutics' average media sentiment score of -0.09 beat Ensysce Biosciences' score of -0.26 indicating that Relmada Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ensysce Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Relmada Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more risk & volatility, ENSC or RLMD? Ensysce Biosciences has a beta of 0.98, meaning that its share price is 2% less volatile than the S&P 500. Comparatively, Relmada Therapeutics has a beta of 0.59, meaning that its share price is 41% less volatile than the S&P 500. Which has preferable valuation & earnings, ENSC or RLMD? Ensysce Biosciences has higher revenue and earnings than Relmada Therapeutics. Ensysce Biosciences is trading at a lower price-to-earnings ratio than Relmada Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEnsysce Biosciences$5.21M0.97-$7.99M-$6.54-0.33Relmada TherapeuticsN/AN/A-$79.98M-$2.51-0.23 Do analysts prefer ENSC or RLMD? Relmada Therapeutics has a consensus price target of $5.00, suggesting a potential upside of 766.55%. Given Relmada Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Relmada Therapeutics is more favorable than Ensysce Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ensysce Biosciences 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Relmada Therapeutics 0 Sell rating(s) 3 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.25 SummaryRelmada Therapeutics beats Ensysce Biosciences on 10 of the 14 factors compared between the two stocks. Get Ensysce Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for ENSC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ENSC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ENSC vs. The Competition Export to ExcelMetricEnsysce BiosciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.12M$2.96B$5.55B$9.41BDividend YieldN/A2.47%3.75%4.03%P/E Ratio-0.3319.7528.0119.82Price / Sales0.97300.10432.6698.27Price / CashN/A42.5936.1658.27Price / Book0.827.678.125.65Net Income-$7.99M-$55.28M$3.25B$257.91M7 Day Performance-1.39%4.85%1.68%3.38%1 Month PerformanceN/A11.70%7.30%11.11%1 Year Performance-67.36%3.69%32.89%18.99% Ensysce Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ENSCEnsysce Biosciences0.566 of 5 stars$2.13-1.4%N/A-69.3%$5.12M$5.21M-0.3310RLMDRelmada Therapeutics4.7492 of 5 stars$0.63+2.9%$5.00+696.8%-85.8%$20.83MN/A-0.2510RVPHReviva Pharmaceuticals2.6921 of 5 stars$0.43+9.7%$9.00+1,996.4%-63.0%$20.61MN/A-0.545Gap UpHigh Trading VolumeFNCHFinch Therapeutics Group0.7891 of 5 stars$12.75flatN/A+706.5%$20.48MN/A-1.45190Positive NewsVYNEVYNE Therapeutics2.9554 of 5 stars$1.33-6.3%$6.25+369.9%-46.0%$20.23M$500K-1.3430Positive NewsHigh Trading VolumeCINGCingulate3.1732 of 5 stars$4.73+8.7%$26.00+449.7%+1,433.7%$20.08MN/A-0.5620BLRXBioLineRx2.5123 of 5 stars$4.70flat$26.00+453.2%-85.9%$20.04M$22.34M-0.5340MEIPMEI Pharma2.1741 of 5 stars$2.94+9.3%N/A+107.0%$19.58MN/A-0.62100Trending NewsHigh Trading VolumeAYTUAytu BioPharma4.2192 of 5 stars$2.15-1.4%$10.00+365.1%-16.8%$19.31M$81M-2.99160Positive NewsHOTHHoth Therapeutics3.1582 of 5 stars$1.43-0.7%$4.00+179.7%+40.4%$18.89MN/A-1.254Positive NewsCARMCarisma Therapeutics3.1981 of 5 stars$0.45+12.7%$1.93+327.0%-65.6%$18.84M$19.63M-0.2920Positive NewsAnalyst Upgrade Related Companies and Tools Related Companies RLMD Alternatives RVPH Alternatives FNCH Alternatives VYNE Alternatives CING Alternatives BLRX Alternatives MEIP Alternatives AYTU Alternatives HOTH Alternatives CARM Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ENSC) was last updated on 7/19/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ensysce Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ensysce Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ENSC Stock Alerts